Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Helene Andrea Sinclair Ingels has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • A.C. Lundstedt

    From the *Department of Microbiological Surveillance and Research, National Neisseria and Streptococcus Reference Center, Statens Serum Institut, Copenhagen, Denmark; †Department of Paediatrics and Adolescent Medicine, ‡Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Denmark; §Department Clinical Biochemistry, Immunology, and Genetics, Statens Serum Institut, Copenhagen, Denmark; and ¶Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark

    1 shared publication
  • Bjørn Kantsø

    Department of Microbiological Diagnostics &Virology, Statens Serum Institut, Copenhagen, Denmark

    1 shared publication
  • Carsten Dmsc Heilmann

    From the *Department of Microbiological Surveillance and Research, National Neisseria and Streptococcus Reference Center, Statens Serum Institut, Copenhagen, Denmark; †Department of Paediatrics and Adolescent Medicine, ‡Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Denmark; §Department Clinical Biochemistry, Immunology, and Genetics, Statens Serum Institut, Copenhagen, Denmark; and ¶Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark

    1 shared publication
  • Hanne V. Marquart

    From the *Department of Microbiological Surveillance and Research, National Neisseria and Streptococcus Reference Center, Statens Serum Institut, Copenhagen, Denmark; †Department of Paediatrics and Adolescent Medicine, ‡Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Denmark; §Department Clinical Biochemistry, Immunology, and Genetics, Statens Serum Institut, Copenhagen, Denmark; and ¶Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark

    1 shared publication
  • Hans-Christian Slotved

    Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark

    1 shared publication
  • Helle Dmsc Konradsen

    From the *Department of Microbiological Surveillance and Research, National Neisseria and Streptococcus Reference Center, Statens Serum Institut, Copenhagen, Denmark; †Department of Paediatrics and Adolescent Medicine, ‡Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Denmark; §Department Clinical Biochemistry, Immunology, and Genetics, Statens Serum Institut, Copenhagen, Denmark; and ¶Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark

    1 shared publication

Latest Publications

  • Open Access

    Serologic response to pneumococcal vaccination in children experiencing recurrent invasive pneumococcal disease

    by Helene A. S. Ingels, Bjørn Kantsø, Hans-Christian Slotved

    Some children are prone to recurrent invasive pneumococcal disease (rIPD) and of these, some respond insufficiently to standard pneumococcal vaccination. Little is known about how to handle these children and if they benefit from additional vaccination. Here, we present results from a nationwide study of pediatric rIPD including data on serotype-specific vaccination response to pneumococcal polysaccharide vaccination (PPV23) and pneumococcal conjugate vaccination (PCV7/13). A retrospective, population-based study was conducted using The National Streptococcus pneumoniae Registry, which contains laboratory-confirmed data from all cases of IPD in Denmark. From January 1980–June 2013 all children aged 0–15 years with rIPD were identified. Clinical data and data on serotype-specific pneumococcal antibody response were collected. Over the years quantification of pneumococcal antibodies varied from being presented in arbitrary units (ELISA), in μg/ml (WHO ELISA) and lately in μg/ml based on Luminex technology. 2482 children were diagnosed with IPD and 75 episodes of rIPD were documented in 59 children. An underlying disease was documented in 45 (76%) children. Vaccination data were available for 26 children; 11 were vaccinated solely with PPV23, 8 with a combination of PPV23 + PCV7, 5 with PCV7 and 2 with PCV13. In total, nine responded to PPV23 vaccination and ten were PPV23 non-responders. Of the 15 PCV vaccinated children, two children responded subnormal to PCV7. Among PPV23 non-responders, five responded to subsequent PCV vaccination. In our population-based study of children with rIPD 53% of the children responded insufficiently to PPV23 vaccination. PPV23 non-responders benefitted from PCV vaccination.


    • 1 July 2015
      • Vol. 62  (7)

    Recurrent invasive pneumococcal disease in children--host factors and vaccination response.

    by Helene Andrea Sinclair Ingels

    Streptococcus pneumoniae is still a leading cause of septicaemia, pneumonia and meningitis in young children world-wide with over half a million children dying annually from pneumococcal disease. Some children are prone to repeated episodes of invasive pneumococcal disease (IPD) because of an underlying predisposing disease. Recurrent IPD (rIPD) is a rarity and published reports on rIPD are limited by having few children included, selected groups of patients or short follow-up periods. Deficiencies in the innate or adaptive immune system have been described in children with rIPD, but the frequency of immunodeficiency among such patients is unknown. The aim of this PhD thesis was to examine paediatric cases of laboratory-confirmed rIPD, over a 33-year period in Denmark, to determine risk factors and study aspects of the immunological background for this problem in children. In October 2007, a seven-valent pneumococcal conjugate vaccine (PCV7) was implemented in the Danish infant immunization programme. An additional aim of the thesis was to examine the impact of vaccination on a population level, following the first three years of general PCV7 vaccination in Denmark. The thesis consists of three papers, which are all directly or indirectly based on data retrieved from the National Streptococcus Pneumoniae Registry. This registry is nationwide and dates back to 1938. The registry contains data from all laboratory-confirmed cases of IPD in Denmark and is continually updated for national surveillance. In Paper 1, we conducted a 33-year retrospective nationwide study of paediatric rIPD. By using data from the National Streptococcus Pneumoniae Registry combined with clinical data from hospital records, we could describe one of the largest known cohorts of children (n:59) with rIPD . We covered epidemiological, microbiological, and clinical features of this clinical entity. Of all children experiencing rIPD, 47% had a known predisposing underlying disease at the time of the rIPD. Most common was immune deficiency due to transplantation. In 19% the episode of rIPD was the clinical manifestation that subsequently led to a diagnosis of an underlying disease. Finally, in 31% of the children no underlying disease was detected. Paper 2 covers data from a follow-up of the cohort of children described in Paper 1. Of this unselected cohort of rIPD, all children without an obvious underlying disease predisposing to pneumococcal disease (such as malignancy, HIV or cerebrospinal-fluid leakage) were invited to participate in the study by undergoing a thorough immunological evaluation. Basic immunological parameters including activity of complement-pathways and T-, B-, NK-cell count were examined in the children and their families. Furthermore, B-cell function including antibody response to polysaccharide-based pneumococcal vaccination and somatic hypermutation was evaluated. Toll like receptor (TLR) signalling function was evaluated in a functional assay. When children with classical risk factors for IPD were excluded, 15 individuals were eligible. Of whom, sex (40%) children with complement C2 deficiency were identified. Moreover, impaired vaccination response was found in six children: three with concurrent C2 deficiency and three with no other immune abnormality. One patient with a severe TLR signalling dysfunction was diagnosed. In Paper 3, we aimed to assess the impact of PCV7 in Denmark following the first three years of infant immunization. By comparing age-specific disease incidences of IPD in the pre-PCV7 (years 2000-2007) and the PCV7 periods (years 2008-2010) we sought to assess direct and indirect effects on incidence of IPD. In addition, changes in pneumococcal serotype distribution and IPD-related mortality were assessed. We documented a marked decline in the incidence of IPD in both vaccinated and non-vaccinated age groups. The overall incidence of IPD among children aged 0-5 years declined from 26.7 to 16.3 cases per 100,000 (IRR 0.58; 95% confidence interval (CI) [0.48-0.69]). A minor but statistically significant increase in the incidence of IPD due to non-vaccine type IPD was observed in both vaccinated and non-vaccinated groups, but with predominance of serotypes covered by the higher valence pneumococcal conjugate vaccines. This thesis confirms the existing knowledge on underlying diseases predisposing children to IPD, such as cerebrospinal fluid leakage, congenital heart disease and malignant diseases. Our findings support the notion that rIPD in a child should prompt a thorough search for an underlying disease. Moreover, our results underline that rIPD in a child without a known predisposing disease is a major pointer towards primary immune deficiency, such as complement deficiency and B cell dysfunction. This is in line with the guidelines put forward by various specialist committees. Finally, we reported data from the first three years of PCV7 vaccination in the Danish immunization programme, suggesting that the vaccine is effective against all serotypes included in the vaccine when administered in a 2+1 schedule.

  • Open Access

    Immunodeficiency Among Children with Recurrent Invasive Pneumococcal Disease

    by Helene Ingels, Lone Schejbel, A.C. Lundstedt, Lise Jensen, Inga A. Laursen, Lars P. Msc Ryder, Niels H.H. Dmsc Heegaard, Helle Dmsc Konradsen, Jens Jørgen Dmsc Christensen, Carsten Dmsc Heilmann, et al.

    Background: Recurrent invasive pneumococcal disease (rIPD) occurs mostly in children with an underlying disease, but some cases remain unexplained. Immunodeficiency has been described in children with rIPD, but the prevalence is unknown. We used a nationwide registry of all laboratory-confirmed cases of rIPD to identify cases of unexplained rIPD and examine them for immunodeficiency. Methods: Cases of rIPD in children 0–15 years of age from 1980 to 2008 were identified. Children without an obvious underlying disease were screened for complement function, T-cell, B-cell, natural killer--cell counts and concentration of immunoglobulins. B-cell function was evaluated by measuring antibody response to polysaccharide-based pneumococcal vaccination and the extent of fraction of somatic hypermutation. Toll-Like receptor (TLR) signaling function and mutations in key TLR-signaling molecules were examined. Results: In total, rIPD were observed in 54 children (68 cases of rIPD of 2192 IPD cases). Children with classical risk factors for IPD were excluded, and among the remaining 22 children, 15 were eligible for analysis. Of these 6 (40%) were complement C2-deficient. Impaired vaccination response was found in 6 children of whom 3 were C2 deficient. One patient had a severe TLR signaling dysfunction. No mutations in IRAK4, IKBKG or MYD88 were found. Conclusion: Of an unselected cohort of children with rIPD at least 11% were C2 deficient. Data suggest that screening for complement deficiencies and deficient antibody response to pneumococcal vaccines in patients with more than 1 episode of IPD is warranted.